Clearmind Medicine Inc. announced the publication of a patent application in Japan for a novel treatment of dyskinesia, a neurological movement disorder, using 3-Methylmethcathinone (3-MMC) alone or combined with Palmitoylethanolamide (PEA), known for its anti-inflammatory and neuroprotective effects. This patent strengthens Clearmind's intellectual property portfolio and supports its collaboration with NeuroThera Labs to develop non-hallucinogenic psychedelic-derived therapies for neurological disorders. The move highlights Clearmind's strategy to build robust IP protection for its innovative treatments and advance clinical-stage neuroplastogen programs targeting various neuropsychiatric and metabolic conditions.
Clearmind Medicine Inc.'s recent patent publication in Japan for a neurological movement disorder treatment comes amid a health sector where 25 of 100 US stocks rose and 68 fell on Pluang. As of Oct 08, 2026 18:11 WIB, notable price moves include ALNY at USD 220.02 with a 1-day change of -1.96% and a typical hold time of 41 days, AMLX at USD 27.89 up 1.68% with a 15-day hold, and CTXR at USD 0.50 down 1.57% with a 16-day hold and strong buy order activity at 90%.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
